Merck's Promising Early Alzheimer's Data Can't Quell Efficacy Concerns

 
• By Lucie Ellis-Taitt
  
Peptid
Will Merck's BACE inhibitor be the first new Alzheimer's drug to market in over a decade? • Source: Shutterstock/Juan Gaertner
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Neurological

More from Therapeutic Category